title: Complications of biologics in inflammatory bowel disease.
abstract: OBJECTIVE
  The treatment of inflammatory bowel disease (IBD) in the modern area has improved with more biological agents available. Although the efficacy of these drugs has been demonstrated, concerns about their safety profile have been raised, and new data have emerged in the past year.
  
  
  RESULTS
  New data regarding the safety profile of anti-TNF were published over the last year, with a better identification of patients at risk of infection, and specific recommendations for the prevention of infections. There is a mild increase in malignancy in patients receiving anti-TNF, mainly lymphoma and skin cancer, which seems mainly attributable to combination with thiopurines. Specific recommendations for management of pregnancy were published.
  
  
  CONCLUSIONS
  Biological treatments are effective and safe in the treatment of IBD, provided that the recommendations for their use and monitoring are followed.
authors.affiliation: Department of Gastroenterology, Hôpital Saint Louis APHP, Paris, France.
authors.forename: Paula
authors.initials: P
authors.lastname: Sousa
authors.forename: Matthieu
authors.initials: M
authors.lastname: Allez
mesh_terms: D001688:Biological Products / Q000009:adverse effects*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D009369:Neoplasms / Q000209:etiology; D009894:Opportunistic Infections / Q000209:etiology / Q000517:prevention & control; D012307:Risk Factors; D014376:Tuberculosis / Q000209:etiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014611:Vaccination
chemical_list: D001688:Biological Products; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha